Drug intelligence / Profile preview

ondansetron + ketorolac + hydromorphone

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Intravenous
01

Overview

A combination of **ondansetron**, **ketorolac**, and **hydromorphone** typically used in multimodal, patient-controlled analgesia (PCA) settings, especially for postoperative pain management. - **Hydromorphone** is a potent semi-synthetic opioid, acting primarily as a mu-opioid receptor agonist, providing strong analgesia for acute and chronic pain. - **Ketorolac** is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and thus pain and inflammation. It is used for its opioid-sparing effect, allowing reduced opioid dosage and associated side effects. - **Ondansetron** is a selective serotonin 5-HT3 receptor antagonist used to prevent or treat nausea and vomiting associated with analgesic therapy or surgery. By combining these agents, this formulation provides synergistic pain relief, minimizes opioid requirements and associated side effects, and controls nausea commonly observed postoperatively[1][2][4]. It is usually administered via intravenous PCA systems in clinical settings[2][3].

Other names
Pre-treatment analgesiaProcedural Analgesia for Liposonix Treatment
02

Targets

HTR3A (5-hydroxytryptamine receptor 3A)PGHS-1 (Prostaglandin G/H Synthase 1)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on ondansetron + ketorolac + hydromorphone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ondansetron + ketorolac + hydromorphone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call